Clinical characteristics of patients analyzed late after allogeneic SCT
| Variable . | Patients, n = 18 . |
|---|---|
| Age, y, median (range) | 43.5 (17-58) |
| Patient sex | |
| Male | 9 |
| Female | 9 |
| Underlying disease | |
| CML | 5 |
| AML | 4 |
| ALL | 4 |
| NHL | 4 |
| MDS | 1 |
| Patient/donor HCMV-serologic status | |
| +/+ | 9 |
| −/+ | 1 |
| +/− | 4 |
| −/− | 4 |
| Conditioning regimen | |
| TBI/CY ± VP16 | 11 |
| BU/CY ± ARA-C | 5 |
| TBI/FLU/CY | 2 |
| Type of donor | |
| HLA-identical family donor | 10 |
| Matched unrelated | 6 |
| Mismatch family | 2 |
| Acute GVHD | |
| Grades 0/I | 11 |
| Grade II | 4 |
| Grades III/IV | 3 |
| Chronic GVHD | |
| None/limited disease | 12 |
| Extensive disease | 6 |
| Variable . | Patients, n = 18 . |
|---|---|
| Age, y, median (range) | 43.5 (17-58) |
| Patient sex | |
| Male | 9 |
| Female | 9 |
| Underlying disease | |
| CML | 5 |
| AML | 4 |
| ALL | 4 |
| NHL | 4 |
| MDS | 1 |
| Patient/donor HCMV-serologic status | |
| +/+ | 9 |
| −/+ | 1 |
| +/− | 4 |
| −/− | 4 |
| Conditioning regimen | |
| TBI/CY ± VP16 | 11 |
| BU/CY ± ARA-C | 5 |
| TBI/FLU/CY | 2 |
| Type of donor | |
| HLA-identical family donor | 10 |
| Matched unrelated | 6 |
| Mismatch family | 2 |
| Acute GVHD | |
| Grades 0/I | 11 |
| Grade II | 4 |
| Grades III/IV | 3 |
| Chronic GVHD | |
| None/limited disease | 12 |
| Extensive disease | 6 |
CML indicates chronic myeloid leukemia; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic syndrome; HCMV, human cytomegalovirus; TBI, total body irradiation; CY, cyclophosphamide; VP16, etoposide; BU, busulfan; FLU, fludarabine; and ARA-C, cytosinarabinoside.